成人免疫性血小板减少症二线治疗的系统性文献综述
该系统综述检索多个医学数据库,最终对186篇文章进行数据提取,评估成人原发免疫性血小板减少症(ITP)二线治疗的安全性和疗效。75%的研究为观察性研究,脾切除术研究最多(n=83,47%),其次为利妥昔单抗(n=49,26%)和血小板生成素受体激动剂罗米司亭(n=34,18%)与艾曲泊帕(n=24,13%)。综述确认大多数二线治疗缺乏来自随机对照试验的严格证据,许多治疗证据有限。
要点
- 75%的研究为观察性研究,近半数在欧洲开展。
- 脾切除术研究最多(n=83,47%),其次为利妥昔单抗(n=49,26%)。
- 仅12项前瞻性随机对照试验涉及利妥昔单抗或TPO-RA。
核心结论
- 综述确认大多数二线ITP治疗缺乏来自随机对照试验的严格证据,许多治疗证据有限。
- 强调需要额外研究指导该场景的治疗选择,并更多使用标准化ITP术语。
研究设计与样本
- 系统性文献综述,使用综合检索词查询多个医学研究数据库,最终对186篇文章进行数据提取。
主要发现
- 大多数(75%)研究为观察性研究,近半数在欧洲开展。
- 脾切除术研究最多(n=83,47%),其次为利妥昔单抗(n=49,26%)、罗米司亭(n=34,18%)和艾曲泊帕(n=24,13%)。
- 识别并详细描述了12项前瞻性随机对照试验,含安慰剂或标准治疗组,评估利妥昔单抗或TPO-RA的安全性和疗效。
- 这些试验在缺乏头对头数据的情况下,提供这些疗法在成人ITP二线治疗中相互比较的见解。
临床怎么用
- 患者管理取决于医生判断和患者偏好,因疾病罕见且缺乏高质量临床试验证据指导实践指南。
局限性
- 大多数二线ITP治疗缺乏来自随机对照试验的严格证据。
- 许多治疗仅有有限证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient management is dependent upon physician judgment and patient preference, given both the rarity of the condition and a paucity of high-quality clinical trial evidence to inform practice guidelines. A systematic literature review was conducted to provide an up-to-date summary of studies evaluating the safety and efficacy/effectiveness of therapies used to treat adults with primary ITP in the second-line setting. Using comprehensive search strings, several medical research databases were queried. Final abstraction was performed on 186 articles. Most (75%) studies were observational in nature; nearly half were conducted in Europe. Splenectomy was the most commonly studied (n = 83, 47%), followed by rituximab (n = 49, 26%) and the thrombopoietin-receptor agonists (TPO-RAs) romiplostim (n = 34, 18%) and eltrombopag (n = 24, 13%). Twelve prospective, randomized controlled trials (RCTs) with a placebo or standard-of-care arm evaluating the safety and efficacy of either rituximab or a TPO-RA were identified and described in detail. These trials provide important information on the safety and efficacy of these treatments, and in the absence of head-to-head data, offer insights on how these therapies compare with one another in treating adult ITP in the second-line setting. This review confirms that for most second-line ITP treatment options, there remains a lack of rigorous evidence derived from RCTs, and for many treatments, there is limited evidence of any kind. The need for additional research to guide treatment choices in this setting and greater use of standardized ITP terminology are highlighted.
引用
- Bylsma LC, Fryzek JP, Cetin K, et al. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol. 2018. PMID: 30264861. doi:10.1002/ajh.25301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。